RxSight, Inc.

For the period ended Jun 30, 2026. Filed Aug 5, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 5, 2026

RXST$4.90+0.8%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Equity

CONDENSED CONSOLIDATED STATEMENTS OFSTOCKHOLDERS’ EQUITY

(In thousands, except number of shares)

Common stock · Additional paid-in · Accumulated other · Accumulated · Total stockholders'
	Shares	Amount	capital	comprehensive loss	deficit	equity
Balance at December 31, 2025	41,242,005	$41	$936,628	$53	$(661,039)	$275,683
Shares issued for the exercise of stock optionsand vesting of restricted stock units	204,323	—	144	—	—	144
Shares redeemed for employee tax withholdings	(62,208)	—	(473)	—	—	(473)
Stock-based compensation expense	—	—	7,945	—	—	7,945
Unrealized loss on short-term investments and cash equivalents, net of tax	—	—	—	(120)	—	(120)
Net loss	—	—	—	—	(15,884)	(15,884)
Balance at March 31, 2026	41,384,120	$41	$944,244	$(67)	$(676,923)	$267,295
Shares issued for the exercise of stock options and vesting of restricted stock units	98,505	—	52	—	—	52
Stock-based compensation expense	—	—	7,465	—	—	7,465
Shares issued for the employee stock purchase plan	102,756	—	617	—	—	617
Unrealized loss on short-term investments and cash equivalents, net of tax	—	—	—	(5)	—	(5)
Foreign currency translation adjustment	—	—	—	13	—	13
Net loss	—	—	—	—	(12,097)	(12,097)
Balance at June 30, 2026	41,585,381	$41	$952,378	$(59)	$(689,020)	$263,340

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(In thousands, except number of shares)

Common stock · Additional paid-in · Accumulated other · Accumulated · Total stockholders'
	Shares	Amount	capital	comprehensive loss	deficit	equity
Balance at December 31, 2024	40,428,220	$40	$903,127	$166	$(622,095)	$281,238
Shares issued for the exercise of stock options and vesting of restricted stock units	210,332	1	696	—	—	697
Shares redeemed for employee tax withholdings	(50,012)	—	(1,418)	—	—	(1,418)
Stock-based compensation expense	—	—	7,140	—	—	7,140
Unrealized loss on short-term investments and cash equivalents, net of tax	—	—	—	(157)	—	(157)
Foreign currency translation adjustment	—	—	—	6	—	6
Net loss	—	—	—	—	(8,190)	(8,190)
Balance at March 31, 2025	40,588,540	$41	$909,545	$15	$(630,285)	$279,316
Shares issued for the exercise of stock options and vesting of restricted stock units	268,485	—	1,362	—	—	1,362
Stock-based compensation expense	—	—	8,547	—	—	8,547
Shares issued for the employee stock purchase plan	56,355	—	705	—	—	705
Unrealized loss on short-term investments and cash equivalents, net of tax	—	—	—	(146)	—	(146)
Foreign currency translation adjustment	—	—	—	14	—	14
Net loss	—	—	—	—	(11,786)	(11,786)
Balance at June 30, 2025	40,913,380	$41	$920,159	$(117)	$(642,071)	$278,012

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.